Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

Inclusion Criteria: 1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999); 2. HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises; 3. Male and female,age between 18 and 70 years; 4. BMI between 18.5-35kg/m2; 5. Willing to be assigned to any treatment arm and sign inform consent. Exclusion Criteria: 1. Type 1 diabetes; 2. Treated by oral or injective antidiabetic drug before screening, including insulin and herb; 3. Fasting plasma glucose \> 13.3 mmol/L (240 mg/dL); 4. Resistant hypertension \[blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least 4 different classes of drugs\]; 5. Plasma triglyceride \> 500 mg/dL (5.65 mmol/L); 6. Is treating by fibrates; 7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy; 8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past 6 months; 9. History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; 10. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG; 11. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase or alanine aminotransferase \> 2.5 fold of the upper limit of the normal range; 12. Kidney diseases or serum creatinine exceed the normal range: male \> 133 μmol/L or female \>108 μmol/L; 13. Had malignancy in the past 5 years, not including basal cell carcinoma; 14. Had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or steroids),beta blockers; 15. Have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors; 16. Edema with unknown reason; 17. Alcohol or drug addiction; 18. Had participated other drugs' clinical trials in the 3 months before screening; 19. Pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct contraception; 20. Any condition that make investigator consider the subject is not suitable to participate the trial.